HighTower Advisors
MDGL icon

HighTower Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

HighTower Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.48M Sell
12,063
-1,851
-13% -$948K 0.01% 1114
2026
Q1 		$7.28M Buy
13,914
+12,741
+1,086% +$6.09M 0.01% 1023
2025
Q4 		$683K Buy
1,173
+46
+4% +$23.5K ﹤0.01% 2398
2025
Q3 		$517K Sell
1,127
-230
-17% -$85.8K ﹤0.01% 2593
2025
Q2 		$411K Sell
1,357
-66
-5% -$19.7K ﹤0.01% 2695
2025
Q1 		$471K Sell
1,423
-54
-4% -$17.7K ﹤0.01% 2508
2024
Q4 		$456K Sell
1,477
-199
-12% -$56K ﹤0.01% 2542
2024
Q3 		$355K Sell
1,676
-108
-6% -$27.6K ﹤0.01% 2682
2024
Q2 		$499K Buy
1,784
+394
+28% +$93.8K ﹤0.01% 2317
2024
Q1 		$370K Buy
1,390
+487
+54% +$115K ﹤0.01% 2514
2023
Q4 		$208K Buy
+903
New +$158K ﹤0.01% 2981
2023
Q1 		– Sell
-720
Closed -$208K – 3566
2022
Q4 		$208K Buy
+720
New +$70.4K ﹤0.01% 2747

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighTower Advisors's MDGL Position: Q2 2026 in Review

HighTower Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 13% in Q2 2026, selling an estimated $948K and leaving 12,063 shares worth $6.48M. The position accounts for 0.01% of the portfolio, ranked #1114.

HighTower Advisors first reported a position in MDGL in Q4 2022 and has held it in 12 quarters since. The position peaked at $7.28M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • HighTower Advisors held 12,063 shares of Madrigal Pharmaceuticals worth $6.48M as of Q2 2026.
  • HighTower Advisors sold 1,851 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $948K.
  • Madrigal Pharmaceuticals made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #1114 holding.
  • HighTower Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • HighTower Advisors's Madrigal Pharmaceuticals position peaked at $7.28M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.